The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

Abivax CEO Marc de Garidel downplayed acquisition rumors and indicated the company plans to pursue equity and debt financing after releasing key Phase 3 trial data for obefazimod in late Q2 2026. With $614.42 million in cash providing runway into Q4 2027, the French biotech aims to strengthen its financial position ahead of potential FDA approval and commercialization, while seeking commercial partners for markets outside the U.S.

Abivax and Nektar Therapeutics are clinical-stage biotech companies with promising drug candidates that could make them attractive acquisition targets. Abivax is developing obefazimod for inflammatory diseases with phase 3 trial data expected in Q2, while Nektar's rezpegaldesleukin shows strong potential for eczema treatment. Both companies have sufficient funding and could be acquired by major pharmaceutical companies at premium valuations.

Cormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage therapies for neurological disorders with strong cash reserves of $926 million.

ACT Capital Management invested $7.25 million in Viking Therapeutics, acquiring 206,100 shares. Viking, a clinical-stage biotech company, is developing obesity and metabolic disorder treatments, with its lead candidate VK2735 showing promising Phase 2 results of up to 14.7% weight reduction. The company has $706 million in cash runway and is advancing multiple clinical programs including Phase 3 trials.

AstraZeneca has exclusive access to Abivax's data room until March 23 as the leading bidder for the French biotech company, which surged 1,600% in 2025 following positive Phase 3 trial results for its ulcerative colitis drug obefazimod. If AstraZeneca fails to submit an offer by the deadline, Eli Lilly and other interested parties could re-enter negotiations. AstraZeneca may have advantages due to its European status and CEO's existing relationship with Abivax's leadership.

Abivax presented 22 abstracts at ECCO 2026 demonstrating obefazimod's anti-fibrotic activity in preclinical models, favorable safety profile comparable to placebo, and rapid symptomatic improvements in ulcerative colitis patients. Biomarker data showed upregulation of miR-124 and reduction of inflammatory cytokines IL-17A and IL-6. The company expects Phase 3 maintenance trial results in Q2 2026 and Phase 2b ENHANCE-CD trial results in Q4 2026.

For investors who missed Eli Lilly's impressive run, two smaller biotech companies offer potential alternatives: Viking Therapeutics is developing VK2735, a weight-loss drug similar to Eli Lilly's Zepbound with phase 3 results expected next year, while Abivax is testing obefazimod for ulcerative colitis with maintenance study results planned for Q2. Both stocks carry high risk but could deliver significant rewards if their clinical trials succeed.

AbbVie, a pharmaceutical giant with strong immunology products like Skyrizi and Rinvoq, is compared against Abivax, an emerging biotech company developing obefazimod for ulcerative colitis. AbbVie offers stability, consistent revenue, and dividend income, making it suitable for risk-averse investors. Abivax presents higher risk but significant upside potential if its drug successfully reaches the market, with possible acquisition prospects.

Abivax stock surged nearly 21% on December 22, 2025, following reports that Eli Lilly is interested in acquiring the France-based biotech company. According to French media, Eli Lilly representatives met with French Treasury officials to discuss regulatory requirements for the acquisition. The interest was likely sparked by Abivax's positive Phase 3 clinical trial results for its ulcerative colitis drug obefazimod. However, the analyst notes that persistent rumors may prevent the deal from commanding a premium price.

Abivax stock surged on market rumors of a potential takeover by Eli Lilly, following impressive clinical trial results for its ulcerative colitis treatment obefazimod.

Abivax reported positive Phase 3 trial results for obefazimod in treating ulcerative colitis, with a 16.4% placebo-adjusted clinical remission rate at Week 8 and no significant safety concerns.